Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK.

scientific article published in December 2007

Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1185/030079907X242575
P698PubMed publication ID17971283

P2093author name stringElke Hunsche
Jeroen P Jansen
Ernest H Choy
Paul Bacon
James Pellissier
Julian T Nash
Andrew Ostor
P433issue12
P407language of work or nameEnglishQ1860
P921main subjectankylosing spondylitisQ52849
P304page(s)3069-3078
P577publication date2007-12-01
P1433published inCurrent Medical Research and OpinionQ5195063
P1476titleEconomic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK.
P478volume23

Reverse relations

cites work (P2860)
Q36894945Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?
Q34610283Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis
Q36818355Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration
Q24235971Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity

Search more.